The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Combining SABR and immunotherapies for NSCLC
Stephanie Kroeze, MD, PhD , University Hospital of Zürich (Universitätsspital Zürich), Zurich, Switzerland, talks on the combination of stereotactic ablative radiotherapy (SABR) with immunotherapy which can be used in all stages of non-small cell lung cancer (NSCLC). There are ongoing studies for stage I and stage II tumors where immunotherapy is added to immunotherapy to prevent distal spread. For stage III NSCLC, SABR is used to control the tumor and prevent distal spread. SABR is used for stage IV NSCLC and oligometastatic disease, the aim is to ablate the tumor as well as to enhance the effects of immunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
